State Board of Administration of Florida Retirement System maintained its position in shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 61,070 shares of the biopharmaceutical company’s stock at the end of the second quarter. State Board of Administration of Florida Retirement System owned approximately 0.09% of Sangamo BioSciences worth $354,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. increased its position in Sangamo BioSciences by 105.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,850,000 shares of the biopharmaceutical company’s stock valued at $11,193,000 after buying an additional 950,000 shares during the period. Prudential Financial Inc. bought a new position in Sangamo BioSciences during the first quarter valued at about $1,384,000. Columbus Circle Investors increased its position in Sangamo BioSciences by 106.7% in the second quarter. Columbus Circle Investors now owns 293,483 shares of the biopharmaceutical company’s stock valued at $1,699,000 after buying an additional 151,487 shares during the period. Royce & Associates LP increased its position in Sangamo BioSciences by 46.1% in the first quarter. Royce & Associates LP now owns 456,100 shares of the biopharmaceutical company’s stock valued at $2,759,000 after buying an additional 144,000 shares during the period. Finally, Spark Investment Management LLC bought a new position in Sangamo BioSciences during the first quarter valued at about $472,000. Institutional investors and hedge funds own 65.24% of the company’s stock.
Sangamo BioSciences Inc. (NASDAQ:SGMO) traded down 5.56% during midday trading on Wednesday, reaching $4.25. The company’s stock had a trading volume of 255,805 shares. Sangamo BioSciences Inc. has a 12-month low of $4.08 and a 12-month high of $9.91. The stock’s 50 day moving average is $4.56 and its 200 day moving average is $5.67. The stock’s market cap is $300.13 million.
Sangamo BioSciences (NASDAQ:SGMO) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.14. The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.38 million. Sangamo BioSciences had a negative return on equity of 36.08% and a negative net margin of 261.81%. Sangamo BioSciences’s revenue for the quarter was down 56.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.17) EPS. Analysts anticipate that Sangamo BioSciences Inc. will post ($1.11) earnings per share for the current year.
Several equities analysts recently weighed in on SGMO shares. Zacks Investment Research downgraded shares of Sangamo BioSciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 5th. Janney Montgomery Scott downgraded shares of Sangamo BioSciences from a “buy” rating to a “neutral” rating and cut their price target for the stock from $15.00 to $8.00 in a report on Thursday, August 4th. Jefferies Group reiterated a “buy” rating on shares of Sangamo BioSciences in a report on Friday, August 5th. Finally, Cowen and Company reiterated a “buy” rating on shares of Sangamo BioSciences in a report on Wednesday, August 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $15.30.
About Sangamo BioSciences
Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.